Zyduslife stock long

**Zydus Lifesciences Ltd. (ZYDUSLIFE) Stock Analysis**

**Company Overview:**
Zydus Lifesciences Ltd. is a leading Indian multinational pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of healthcare products, including human formulations, active pharmaceutical ingredients (APIs), animal health products, and consumer wellness items. The company's product portfolio spans various therapeutic areas, such as oncology, autoimmune diseases, nephrology, inflammation, rheumatology, hepatology, and infectious diseases.

**Fundamental Analysis:**

- **Market Capitalization:** Approximately ₹89,086 crore. citeturn0search0

- **Price-to-Earnings (P/E) Ratio:** The stock is trading at a P/E ratio of 19.63, which is below the industry average of 32.70, indicating potential undervaluation. citeturn0search5

- **Earnings Per Share (EPS):** ₹45.09, reflecting the company's profitability. citeturn0search5

- **Return on Equity (ROE):** 19.72%, demonstrating efficient use of shareholders' equity to generate profits. citeturn0search5

- **Debt-to-Equity Ratio:** 0.01, indicating a minimal level of debt in the company's capital structure. citeturn0search5

- **Dividend Yield:** 0.34%, reflecting a conservative dividend payout policy. citeturn0search5

**Technical Analysis:**

- **Current Price:** ₹885.35. citeturn0search8

- **52-Week Range:** The stock has traded between ₹855.10 and ₹1,324.30 over the past year, indicating significant volatility. citeturn0search8

- **Support Levels:**
- First Support: ₹880.00
- Second Support: ₹850.00

- **Resistance Levels:**
- First Resistance: ₹1,000.00
- Second Resistance: ₹1,100.00

- **Breakout Point:** A sustained move above ₹1,000.00 could signal the start of a bullish trend.

- **Retest Levels:** After a breakout above ₹1,000.00, a retest of this level would confirm its strength as new support.

**Recent Performance:**

- **1 Week:** The stock has decreased by 1.74%. citeturn0search8

- **1 Month:** The stock has decreased by 2.97%. citeturn0search1

- **6 Months:** The stock has decreased by 1.16%. citeturn0search6

**Analyst Ratings:**

- ICICI Direct has set a target price of ₹500.00 for Zydus Lifesciences Ltd., suggesting a potential downside of approximately 43% from the current market price. citeturn0search1

- Alpha Spread reports an average 1-year price target of ₹1,097.92, with a low forecast of ₹824.16 and a high forecast of ₹1,400.00, indicating a potential upside of up to 58% from the current market price. citeturn0search4

**Conclusion:**
Zydus Lifesciences Ltd. exhibits strong fundamentals with efficient use of equity and minimal debt. Technically, the stock is trading near its support levels, indicating potential for upward movement if these levels hold. Investors should monitor the breakout above ₹1,000.00 and consider the support levels at ₹880.00 and ₹850.00 for potential entry points.

*Please note that stock market investments carry inherent risks. It is advisable to conduct thorough research or consult with a financial advisor before making investment decisions.*